Actively Recruiting
Comprehensive Clinical Evaluation Study of GLP-1RA
Led by LI YAN · Updated on 2024-11-13
492
Participants Needed
1
Research Sites
108 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The objective of this project is to identify the most efficacious glucagon-like peptide-1 receptor agonists (GLP-1RAs) for the treatment of adult patients with type 2 diabetes mellitus (T2DM). In accordance with the index system and evaluation rules set forth in the Management Guidelines for Comprehensive Clinical Evaluation of Drugs, the effects of GLP-1RAs drugs in real-world settings are tracked, summarised, and analysed across six dimensions: safety, effectiveness, economy, innovation, appropriateness, and accessibility. This is done with the objective of ensuring that these drugs are fully utilised in accordance with their potential benefits. The objective is to ascertain the role of medical institutions as the principal entity responsible for the comprehensive evaluation of the clinical application of drugs and to provide data that will reduce the risk of using GLP-1RAs drugs. Moreover, the objective is to ascertain the advantages of their clinical application and to guarantee the safe and rational use of drugs for patients with type 2 diabetes mellitus. The objective of this study is to facilitate the fulfilment of medical institutions' role as the primary entity responsible for the comprehensive evaluation of the clinical application of medicines. Furthermore, the study will provide data that can be used to reduce the risk of using GLP-1RAs drugs, explore the advantages of their clinical application, and guarantee the safe and rational use of medicines for patients with type 2 diabetes.
CONDITIONS
Official Title
Comprehensive Clinical Evaluation Study of GLP-1RA
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with type 2 diabetes
- No study drug used in the last three months
- Current hypoglycemic treatment includes investigational drugs
- Age 18 years or older
- Complete demographic data, disease history, medical records, lab tests, and drug use information
- Signed informed consent form
You will not qualify if you...
- Persistent influenza, autoimmune disease, or other metabolic diseases
- Presence of significant gastrointestinal diseases, gastrointestinal surgery, or malabsorption syndrome
- Using diet drugs, glucocorticoids, or drugs affecting gastrointestinal movement
- Severe liver or kidney function impairment or having malignant tumors
- Pregnant or breastfeeding women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Yan Li
Jinan, China
Actively Recruiting
Research Team
D
Dong Zhonghua The First Affiliated Hospital of Shandong First Medical Univer, master
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here